阻塞性睡眠呼吸暂停综合征的临床研究

强调对阻塞性睡眠呼吸暂停综合征的认识，以达到对该病的早期诊与治疗。方法应用Ａｕｔｏｓｅｔ诊疗系统及鼻持续正压通气治疗仪，对６６例ＯＳＡＳ患者进行确诊及序贯治疗。     

替代神经吻合法治疗喉返神经麻痹的解剖学研究

通过对30例人喉神经、膈神经、颈袢的解剖观测及利用图象分析仪二维重建技术对相关神经的截面积、纤维数量的测量比较分析,结合有关实验研究资料,设计了在甲状软膏板后下方开窗,于甲杓肌神经起点处切断该神经,用颈袢主支与甲杓肌神经吻合,用膈神经与喉下神经吻合,同时重建声带的内收和外展功能,并探讨了其解剖和生理学基础,认为此手术方法治疗喉返神经麻痹比较理想和可行。     

Recommendations for the reporting of larynx specimens containing laryngeal neoplasms

The Association of Directors of Anatomic and Surgical Pathology have developed recommendations for the surgical pathology reporting of common malignant tumors. The recommendations for carcinoma of the larynx are reported herein.     

The haemodynamic response to the insertion of the laryngeal mask airway: a comparison with laryngoscopy and tracheal intubation

The haemodynamic response to the insertion of the laryngeal mask airway (LMA) was assessed and compared to that of laryngoscopy and tracheal intubation in a study of forty patients (ASA 1) randomly allocated into two groups and anaesthetised using a standard balanced anaesthetic technique. The results show that the changes in all cardiovascular parameters measured following LMA insertion were significantly less (P<0.05) when compared with those following laryngoscopy and tracheal intubation. We conclude that airway management with the LMA may be used to avoid the haemodynamic response to tracheal intubation where such a response is undersirable.     

PTEN基因在喉鳞癌中的表达及意义

目的:探讨蛋白酪氨酸磷酸酶基因(PTEN)在喉鳞癌中的表达及其临床意义.方法:应用半定量RTPCR方法检测喉癌组织中PTEN mRNA的表达.结果:淋巴结转移组喉癌较正常喉组织PTEN mRNA表达下降有统计学意义(P＜0.05).病理低分化与高分化相比,PTEN mRNA表达差异有统计学意义(P＜0.05).结论:PTEN基因表达下降在喉鳞癌演进中起重要作用.     

肾上腺髓质素对内皮素促家兔气道平滑肌细胞增殖的抑制作用

在体外培养的家兔气道平滑肌细胞（ＡＳＭＣ）上，观察肾上腺髓质素（ＡＭ）对内皮素（ＥＴ）促ＡＳＭＣ增殖的影响及丝裂素活化蛋白激酶（ＭＡＰＫ）活性的变化。以探讨ＡＭ对ＡＳＭＣ增殖的调控。结果显示１０－８ｍｏｌ／ＬＥＴ－１显著刺激ＡＳＭＣ３Ｈ－ＴｄＲ参入及ＭＡＰＫ激活（Ｐ＜０．０１）。ＡＭ（１３－５２）呈剂量依赖地抑制ＥＴ－１的上述作用（Ｐ＜０．０５，Ｐ＜０．０１）。单独应用ＡＭ（１３－５２）对ＡＳＭＣ３Ｈ－ＴｄＲ参入及ＭＡＰＫ活性无明显影响。表明ＡＭ（１３－５２）可抑制ＡＳＭＣ对ＥＴ－１的增殖反应，其机理可能涉及ＭＡＰＫ活性的抑制。     

Antimuscarinic effect of tiquizium bromide in vitro and in vivo

Objective: We studied the bronchodilatory effect of tiquizium bromide [3-(di-2-thienylmethylene)-5-methyl-trans-quinolizidinium bromide; TQZ], an antimuscarinic agent, on airway smooth muscle in vitro, and also in patients with chronic obstructive pulmonary disease (COPD). Methods: In the first experiment, canine tracheal smooth muscle was used to measure the pA2 of TQZ in vitro. The selectivity of TQZ for muscarinic receptor subtypes was also examined with a radioligand binding assay. Results: The pA2 value of TQZ was 8.75. The pK _i values of TQZ for M1, M2, and M3 were 8.70, 8.94, and 9.11, respectively. In an open pilot experiment, the effects of TQZ inhalation were studied in seven patients with COPD (seven men, mean age 68.5 years). TQZ significantly increased forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV₁) in a dose-dependent manner. The mean maximum increases in FVC and FEV₁ caused by inhaled TQZ (2.0 mg) were 24% and 29%, respectively, and they were measured 1 h after the drug had been inhaled. The FVC and FEV₁ were still significantly higher than the control values even 8 h after the drug had been inhaled. No adverse effects were observed after inhalation of TQZ. Conclusion: These data suggest that TQZ is an effective antimuscarinic agent, and that it causes significant bronchodilation in patients with COPD. Received: 3 April 1995/Accepted in revised form: 27 November 1995     

Possible site of bronchodilation due to inhaled procaterol aerosol in asthmatic patients

Summary We studied the effective site of an inhaled aerosol of procaterol, a ₂-selective adrenergic bronchodilator, in 8 asthmatic patients whose basal lung functions are almost within the normal range in both slow vital capacity (VC) and forced expiratory volume in one second (FEV_1.0), and are free from asthmatic attack. In patients who had received procaterol 30 min after inhalation of aerosol, there was no significant change in VC, although FEV_1.0, maximal expiratory flow at 50% VC , maximal expiratory flow at 25% VC and maximal expiratory flow at 30% VC of partial maximal expiratory flow volume curve improved significantly. On the other hand, in those who had received placebo, none of the parameters changed. Furthermore, Rl decreased and C_0.5 increased significantly during the first 5 min after inhalation of procaterol aerosol. After an interval of 5 min, Rl did not change any further, while C_0.5 continued to improve until 30 min after inhalation of procaterol. These results suggest that procaterol may first dilate the large airway and then may gradually dilate the small airway in bronchial asthma.